News

Zacks.com on MSN20h
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.
BioSpace20h
Following Rejection, FDA Okays Sanofi/Regeneron’s Dupixent for Chronic Hives
Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...
pharmaphorum19h
Sanofi's Dupixent gets FDA nod for chronic hives indication
Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...
STAT20h
FDA approves blockbuster Dupixent for chronic hives
The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...
Medical Dialogues18h
FDA Approves Dupilumab as First New Targeted Therapy for Chronic Spontaneous Urticaria in Over a Decade
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous ...
PharmExec23h
Sanofi Advances Mid- to Late-Stage Respiratory Pipeline, Targeting Unmet Need in Asthma, COPD
New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...
STAT20h
Pharmalittle: We’re reading about a Novo challenge to Medicare talks, a scuttled FDA office, and more
Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...
Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type
Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...
Contract Pharma18h
FDA Approves Dupixent in the U.S. for Chronic Spontaneous Urticaria
The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) to treat adults and ...
WebMD3h
FDA Approves Dupixent for Chronic Skin Condition
The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular ...
Regeneron Pharmaceuticals, Inc.: Regeneron Provides Update on EYLEA HD (aflibercept) Injection 8 mg Supplemental Biologics License Application
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter ...